Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
AGIO
AGIO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AGIO News
Agios Halts Development of LR-MDS Drug Tebapivat
2d ago
Newsfilter
Regulatory Approvals and Collaborations in Biotech Sector
1d ago
NASDAQ.COM
Agios Pharmaceuticals Halts Blood Cancer Treatment Trials
2d ago
seekingalpha
Agios Receives EU Approval for PYRUKYND
5d ago
NASDAQ.COM
Avanzanite Launches PYRUKYND in the EU
May 22 2026
Newsfilter
PYRUKYND Approved in EU for Thalassemia Treatment
May 22 2026
Newsfilter
Agios Pharmaceuticals Presents New Data on Mitapivat at EHA 2026
May 12 2026
Newsfilter
Agios Submits sNDA for Accelerated Approval of Mitapivat in Sickle Cell Disease
May 12 2026
Newsfilter
Agios Pharmaceuticals Shares Rise 11.2% Following Strong Earnings Report
May 02 2026
Fool
Agios Pharmaceuticals Shares Surge 13.11% After Earnings Report
Apr 29 2026
Fool
Agios Pharmaceuticals Reports $21 Million Revenue in Q1
Apr 29 2026
NASDAQ.COM
Agios Pharmaceuticals Q1 2026 Earnings Call Highlights
Apr 29 2026
seekingalpha
Agios Pharmaceuticals Q1 2026 Earnings Highlights
Apr 29 2026
seekingalpha
Agios Pharmaceuticals Reports Strong Q1 2026 Financial Results and Strategic Updates
Apr 29 2026
Newsfilter
Agios Pharmaceuticals to Announce Q1 Earnings on April 29
Apr 28 2026
seekingalpha
Agios Pharmaceuticals Stock Hits Oversold Territory
Apr 27 2026
NASDAQ.COM
Show More News
